LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
STRO
Sutro Biopharma, Inc.
There isn't enough reported data to score STRO yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STRO Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
STRO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STRO PE Valuation
STRO has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
STRO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect STRO's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus STRO down 258%.
STRO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$25.50 | -$9.40 |
| Q2 2025 | -$24.70 | -$6.40 |
| Q1 2025 | -$29.20 | -$10.40 |
| Q4 2024 | -$29.60 | -$11.80 |
| Q3 2024 | -$16.10 | +$12.80 |
| Q2 2024 | -$18.30 | +$6.20 |
| Q1 2024 | -$18.80 | +$4.80 |
| Q4 2023 | -$17.80 | +$5.70 |
STRO lost $25.50 per share over the past year, a bigger loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over STRO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STRO on profitability, with a higher operating margin.
STRO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.1M | -6.1% |
| Q2 2026 | $9.8M | -85% |
| Q1 2026 | $14.5M | -17% |
| Q4 2025 | $11.6M | -21% |
| Q3 2025 | $9.7M | +14% |
| Q2 2025 | $63.7M | +148% |
| Q1 2025 | $17.4M | +34% |
| Q4 2024 | $14.8M | -87% |
STRO's revenue has slid since its 2023 peak: $9M last quarter, down 6.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -241% | +259 points |
| Q2 2026 | -304% | -299 points |
| Q1 2026 | -204% | +190 points |
| Q4 2025 | -327% | +114 points |
| Q3 2025 | -500% | +297 points |
| Q2 2025 | -5.3% | +184 points |
| Q1 2025 | -394% | +41 points |
| Q4 2024 | -441% | -479 points |
STRO's operating margin was −241% last quarter, up 259 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over STRO on cash generation, producing positive trailing cash flow while its opponent burns cash.
STRO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$22.5M | +$15.7M |
| Q2 2026 | -$38.3M | +$6.4M |
| Q1 2026 | -$42.3M | +$25.6M |
| Q4 2025 | -$26.4M | +$45.3M |
| Q3 2025 | -$38.2M | +$26.3M |
| Q2 2025 | -$44.7M | -573% |
| Q1 2025 | -$67.9M | -$3.1M |
| Q4 2024 | -$71.7M | -610% |
STRO has burned cash in almost every quarter: −$129M over the past year, against −$223M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STRO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STRO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +12.2K shares |
| 1 year | +96% | +8.1M shares |
| 3 years | +175% | +10.5M shares |
| 5 years | +260% | +12M shares |
| Available history | +622% | +14.3M shares |
STRO has 17M diluted shares, up 96% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STRO Net Leverage
STRO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STRO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.4 | Neutral |
| Stochastic | 7.3 | Oversold |
STRO's weekly RSI is 30 (neutral) and its Stochastic is 7 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STRO PE vs Healthcare Sector
STRO has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STRO on trend strength, trading above more of its moving averages.
STRO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.8 | 19% below |
| 20 week MA | $18.2 | 47% below |
| 50 week MA | $20.7 | 54% below |
| 100 week MA | $15.8 | 39% below |
| 200 week MA | $29.0 | 67% below |
STRO is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STRO on returns for 2026, with the stronger performance.
STRO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $109.8 | $220.8 | +101% |
| 2021 | $220.8 | $142.5 | -35% |
| 2022 | $142.5 | $68.7 | -52% |
| 2023 | $68.7 | $42.9 | -38% |
| 2024 | $42.9 | $18.9 | -56% |
| 2025 | $18.9 | $11.5 | -39% |
| 2026 YTD | $11.5 | $9.59 | -17% |
STRO has finished five years in a row lower, and it's down 17% so far in 2026.